For the record, my issue with critical psychiatry is this. Baseline, they think they are so different but actually are one of the same. 1. It stops seeing me. It assumes everything I say is to maintain the "sick role". From this position, anything I say is warped. 1/

‘Science’s “Savage Slot”: The appropriation and erasure of Indigenous science in the psychedelic renaissance’ by @emiliasana.bsky.social www.sciencedirect.com/science/arti...

Classical randomized controlled trials (RCTs) can't capture the complexity of psychedelic therapy. In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.

New paper out with @tehseennoorani.bsky.social @maxwolff.bsky.social and orhers, showing that the UK Medical Research Council's framework for complex interventions offer an important way foward for the field of #psychedelics: journals.sagepub.com/doi/epub/10....

If you're anywhere in Australia at the end of Nov then I'd suggest you make your way here. This is the first outdoor entheogenesis conference in 8 yrs. An incredible event with a sharp line up of speakers. @mikejay.bsky.social @tehseennoorani.bsky.social @pyrodelic.bsky.social @gmantic.bsky.social

A few moments from our ongoing MESEC 2025 Workshop (‘Centering Experience in Mental Health: Uniting Psychiatry and Consciousness Science’) at the beautiful Lago di Bolsena! @lucieberko.bsky.social @tehseennoorani.bsky.social

How much is the psychedelic experience influenced by what we see, hear and read? We made a way to measure it: The Psychedelic Media Exposure Questionnaire - developed by Audrey Evers, Chris Kelly, @shaylalove.bsky.social , @tehseennoorani.bsky.social, validated on >600 respondents. Link below:

A promising approach

www.journals.uchicago.edu/doi/abs/10.1... This was a great read and I'm sorry to have missed it until now. Offers a "rendi epistemology", reviving the lost figure of the rend - the “pious rogue” of Islamicate drug histories - as a way of moving beyond coloniality/modernity in drug studies

New in @naturemedicine.bsky.social "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by Chloé Pronovost-Morgan, Kyle Greenway, myself, and many ReSPCT Experts." nature.com/articles/s41...

Sharing this "Mad in America" review of our recent article on the commercialisation of psychedelic integration www.madinamerica.com/.../from-hea... The link to the original article (co-written with Luís Fernando Tófoli) is in the comments below

Australia was the first country to permit prescribing MDMA outside clinical trials. This creates a fascinating situation where a treatment is accessible but no approved products exist. This is important to watch as it might tell us something about what will happen in the US when FDA approval occurs.

Excited to see the publication of our commentary on the need for a better psychedelic safety net. Much appreciation to @philosojules.bsky.social and CPEP for being such a catalyst for good work on this topic! onlinelibrary.wiley.com/doi/10.1176/...

Just came across this fascinating 2024 DMT study I missed - participants who were interrupted during their DMT experience (by having to give ratings) showed significantly less reduction in depressive symptoms compared to those left undisturbed. Important implications for psychedelic therapy. 🧵

Hard not to see these arrangements from our 2 year old at the end of each night as provocations

Sarah Zeines asks if hospitals are the best setting for psychedelic medicine, following some patients' complaints about Swiss PAT programme. Includes comments from @tehseennoorani.bsky.social @beccakacanda.bsky.social @jameslkent.bsky.social + many others. www.ecstaticintegration.org/p/are-hospit...

www.frontiersin.org/journals/psy... A welcome philosophical intervention on the topic of experiential knowledge! Brings the EK literature up to date, in ways that interface with cog sci & is rich for those wanting to analyse knowledge of psychedelics based upon experience (as opposed2eg trial data)

Lovely short piece on psychedelic trip intention-making as rite of sacralization

I encourage everyone to read through Compass' latest description of their "psychological support" model. If this is not in fact psychotherapy, then nothing is. Ironically, this is most evident whenever the authors apparently aim to differentiate their model from (their idea of) psychotherapy, e.g.:

Another one! Every region should have a @mikejay.bsky.social reading group

www.nplusonemag.com/issue-49/ess... This analysis of the state of Netflix film production has some great one liners, including customer experience as “managed dissatisfaction”, a movie as “an accounting trick”, and movies as “designed to be played but not watched”

It's been another very busy year at Psychedelic Alpha! To kick off our 2024 Year In Review, I look back at 11 of our stories from the year gone by: from the Lykos saga through to funding grants from NIDA and the EU... psychedelicalpha.com/news/psyched...

Call for submissions! Join us in Basel for the 2025 Basel-Oxford-NUS Experimental Bioethics -- BioXPhi -- Summit | Hosted at the Institute for Biomedical Ethics | University of Basel - JUNE 25-27, 2025. Co-sponsored @NUS_CBmE @ethicsinthenews

exeter.ac.uk/study/online/courses/msc-psychedelics/ The world’s first* master’s degree in Psychedelics: Mind, Medicine, and Culture is now open for enrolment. Join the wonderful group at Exeter for a phantastic online course that covers psychedelia via science, philosophy, and much more.

Useful analysis & examples complicating the polarised discourse that has given rise to ‘pill-shaming’ around psych meds

We’re launching the Monash Psychedelic Education Program in 2025! Registrations are NOW OPEN for undergraduate and postgraduate education in psychedelic science and therapies! Options for EVERYONE, ANYWHERE. Clinical training coming in 2026! Visit: www.monash.edu/psychedelic-education

Community Strategising about Psychedelic Therapy in Aotearoa is an 18-month, philanthropically-funded project to cultivate relationships within and between communities who have a stake in the roll-out of psychedelic therapies in Aotearoa New Zealand.